

# Deli Huang

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/5740813/deli-huang-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

44  
papers

3,415  
citations

20  
h-index

50  
g-index

50  
ext. papers

4,713  
ext. citations

17.9  
avg, IF

5.31  
L-index

#	Paper	IF	Citations
44	Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. <i>Science</i> , <b>2020</b> , 369, 956-963	33.3	906
43	Translocation of mixed lineage kinase domain-like protein to plasma membrane leads to necrotic cell death. <i>Cell Research</i> , <b>2014</b> , 24, 105-21	24.7	500
42	Broad neutralization of SARS-related viruses by human monoclonal antibodies. <i>Science</i> , <b>2020</b> , 369, 731-736	33.3	376
41	Structural basis of a shared antibody response to SARS-CoV-2. <i>Science</i> , <b>2020</b> , 369, 1119-1123	33.3	338
40	Diverse sequence determinants control human and mouse receptor interacting protein 3 (RIP3) and mixed lineage kinase domain-like (MLKL) interaction in necroptotic signaling. <i>Journal of Biological Chemistry</i> , <b>2013</b> , 288, 16247-16261	5.4	177
39	Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody. <i>Science</i> , <b>2021</b> , 371, 823-829	33.3	157
38	Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate. <i>Science</i> , <b>2020</b> , 370, 1089-1094	33.3	153
37	Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants. <i>Science</i> , <b>2021</b> , 373, 818-823	33.3	148
36	Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection. <i>Nature Communications</i> , <b>2021</b> , 12, 2938	17.4	110
35	PLD3 and PLD4 are single-stranded acid exonucleases that regulate endosomal nucleic-acid sensing. <i>Nature Immunology</i> , <b>2018</b> , 19, 942-953	19.1	56
34	HIV-1 vaccine design through minimizing envelope metastability. <i>Science Advances</i> , <b>2018</b> , 4, eaau6769	14.3	43
33	Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection <b>2020</b> ,		40
32	Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model <b>2020</b> ,		35
31	A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody. <i>PLoS Pathogens</i> , <b>2020</b> , 16, e1009089	7.6	33
30	Commercial Serology Assays Predict Neutralization Activity against SARS-CoV-2. <i>Clinical Chemistry</i> , <b>2021</b> , 67, 404-414	5.5	32
29	Reprogramming the antigen specificity of B cells using genome-editing technologies. <i>ELife</i> , <b>2019</b> , 8,	8.9	30
28	A protective broadly cross-reactive human antibody defines a conserved site of vulnerability on beta-coronavirus spikes <b>2021</b> ,		26

27	Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants <b>2021</b> ,		26
26	Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens. <i>PLoS Pathogens</i> , <b>2020</b> , 16, e1008665	7.6	25
25	A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection. <i>Cell Host and Microbe</i> , <b>2021</b> , 29, 806-818.e6	23.4	24
24	B cells expressing authentic naive human VRC01-class BCRs can be recruited to germinal centers and affinity mature in multiple independent mouse models. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2020</b> , 117, 22920-22931	11.5	20
23	Broad sarbecovirus neutralizing antibodies define a key site of vulnerability on the SARS-CoV-2 spike protein <b>2020</b> ,		18
22	Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern. <i>Science Translational Medicine</i> , <b>2021</b> , 13, eabj5413	17.5	18
21	Vaccine elicitation of HIV broadly neutralizing antibodies from engineered B cells. <i>Nature Communications</i> , <b>2020</b> , 11, 5850	17.4	17
20	A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection.. <i>Science Translational Medicine</i> , <b>2022</b> , 14, eabi9215	17.5	15
19	Structural basis of a public antibody response to SARS-CoV-2 <b>2020</b> ,		14
18	An Engineered Antibody with Broad Protective Efficacy in Murine Models of SARS and COVID-19 <b>2020</b> ,		11
17	SARS-CoV-2 Serology Status Detected by Commercialized Platforms Distinguishes Previous Infection and Vaccination Adaptive Immune Responses. <i>Journal of Applied Laboratory Medicine</i> , <b>2021</b> , 6, 1109-1122	2	10
16	Regulator of G-protein signaling 19 (RGS19) and its partner G $\alpha$ inhibiting activity polypeptide 3 (GNAI3) are required for zVAD-induced autophagy and cell death in L929 cells. <i>PLoS ONE</i> , <b>2014</b> , 9, e94634 <sup>27</sup>	3.7	9
15	Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate <b>2020</b> ,		8
14	Commercial Serology Assays Predict Neutralization Activity Against SARS-CoV-2		7
13	Diverse immunoglobulin gene usage and convergent epitope targeting in neutralizing antibody responses to SARS-CoV-2. <i>Cell Reports</i> , <b>2021</b> , 35, 109109	10.6	7
12	Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants <b>2021</b> ,		6
11	Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques		4
10	A pandemic-enabled comparison of discovery platforms demonstrates a naïve antibody library can match the best immune-sourced antibodies.. <i>Nature Communications</i> , <b>2022</b> , 13, 462	17.4	3

9	SARS-CoV-2 Serology Status Detected by Commercialized Platforms Distinguishes Previous Infection and Vaccination Adaptive Immune Responses <b>2021</b> ,	3
8	A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection <b>2021</b> ,	3
7	Cleavage of DNA and RNA by PLD3 and PLD4 limits autoinflammatory triggering by multiple sensors. <i>Nature Communications</i> , <b>2021</b> , 12, 5874	17.4 2
6	A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody <b>2020</b> ,	2
5	In vivo engineered B cells retain memory and secrete high titers of anti-HIV antibodies in mice	1
4	Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens <b>2020</b> , 16, e1008665	
3	Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens <b>2020</b> , 16, e1008665	
2	Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens <b>2020</b> , 16, e1008665	
1	Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens <b>2020</b> , 16, e1008665	